Search Within

Saad Zafar Usmani

Formats
  1. Meeting Abstract (218)
  2. Journal Article (72)
  3. Review (16)
  4. Research Letter (11)
  5. Correspondence (4)
  6. Editorial (4)
  7. Guidelines (2)
  8. Book Section (1)
Groups
  1. Hematologic Malignancies, Division of (163)
  2. Department of Medicine (160)
  3. Center for Hematologic Malignancies (155)
  4. Graduate Medical Education (144)
  5. Myeloma (143)
  6. GME, Medicine (135)

More Groups

People
  1. Alexander Lesokhin (124)
  2. Kylee Maclachlan (121)
  3. Sham Mailankody (109)
  4. Urvi Shah (107)
  5. Carlyn Rose Tan (102)
  6. Neha Korde (99)

More People

Years
  1. 2025 (25)
  2. 2024 (97)
  3. 2023 (123)
  4. 2022 (83)
Publications
  1. Blood (109)
  2. Clinical Lymphoma, Myeloma and Leukemia (80)
  3. Journal of Clinical Oncology (30)
  4. Blood Cancer Journal (15)
  5. Blood Advances (14)
  6. Oncology Research and Treatment (7)

More Publications

Publishers
  1. American Society of Hematology (123)
  2. Elsevier Inc. (92)
  3. American Society of Clinical Oncology (30)
  4. Nature Publishing Group (22)
  5. Elsevier Science, Inc. (10)
  6. S. Karger AG (7)

More Publishers

Results (328)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Geometric network analysis defines poor-prognosis subtypes in multiple myeloma
    Meeting Abstract

    Simhal, A. K.; Maclachlan, K. H.; Elkin, R.; Zhu, J.; Usmani, S.; Keats, J. J.; Norton, L.; Deasy, J. O.; Oh, J. H.; Tannenbaum, A.
    Blood (2022)

    Fulltext@MSK | Save
  • Daratumumab plus lenalidomide, bortezomib, and dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients (Pts): Final analysis of griffin among clinically relevant subgroups
    Meeting Abstract

    Chari, A.; Kaufman, J. L.; Laubach, J. P.; Sborov, D. W.; Reeves, B.; Rodriguez, C.; Silbermann, R.; Costa, L. J.; Anderson, L. D. Jr; Nathwani, N.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in transplant-ineligible patients (Pts) with newly diagnosed multiple myeloma (NDMM): Clinical assessment of key subgroups of the phase 3 MAIA study
    Meeting Abstract

    Moreau, P.; Facon, T.; Usmani, S.; Bahlis, N. J.; Raje, N.; Plesner, T.; Orlowski, R. Z.; Basu, S.; Nahi, H.; Hulin, C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • The mutagenic impact of radiotherapy in multiple myeloma
    Meeting Abstract

    Diamond, B.; Poos, A. M.; Ziccheddu, B.; Maclachlan, K. H.; Zhang, Y.; Usmani, S.; Boyle, E. M.; Davies, F. E.; Morgan, G. J.; Landgren, O.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Belantamab mafodotin in patients with relapsed/refractory multiple myeloma, a real-world single center experience
    Meeting Abstract

    Hultcrantz, M.; Derkach, A.; Hassoun, H.; Korde, N.; Maclachlan, K. H.; Mailankody, S.; Patel, D.; Shah, U. A.; Tan, C.; Akhlaghi, T.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A randomized placebo controlled study of a plant-based dietary versus supplement versus placebo intervention in patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) - the Nutrition Prevention (NUTRIVENTION-3) study
    Meeting Abstract

    Shah, U. A.; Castro, F.; Anuraj, A.; Schach, E.; Derkach, A.; Joseph, N. S.; Adintori, P. A.; Guttentag, L.; Blaslov, J.; Cross, J. R.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A pilot plant based dietary intervention in MGUS and SMM patients with elevated BMI is feasible and associated with improvements in metabolic and microbiome biomarkers of progression
    Meeting Abstract

    Shah, U. A.; Derkach, A.; Castro, F.; Anuraj, A.; Blaslov, J.; Tran, L.; Adintori, P. A.; Burge, M.; Funkhouser, S.; Hosszu, K.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Efficacy outcomes and characteristics of patients with multiple myeloma (MM) who achieved sustained minimal residual disease negativity after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1
    Meeting Abstract

    Munshi, N. C.; Paiva, B.; Martin, T.; Usmani, S.; Lin, Y.; Schecter, J. M.; Jackson, C. C.; Madduri, D.; Zudaire, E.; Yeh, T. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase 2 trial of colesevelam for lenalidomide-associated diarrhea
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Korde, N.; Mailankody, S.; Shekarkhand, T.; Burge, M.; Maclachlan, K. H.; Patel, D.; Shah, U. A.; Chung, D. J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Teclistamab population pharmacokinetics and exposure-response relationship support 1.5 Mg/Kg dose regimen in relapsed/refractory multiple myeloma
    Meeting Abstract

    Miao, X.; Wu, L. S.; Wang Lin, S. X.; Xu, Y.; Chen, Y.; Iwaki, Y.; Kobos, R.; Stephenson, T.; Kemmerer, K.; Uhlar, C. M.; more...
    Blood (2022)

    Fulltext@MSK | Save